The Food and Drug Administration yesterday updated its Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioid analgesics, and extended the same requirements to immediate-release opioid analgesic products. The REMS applies to 347 opioid analgesics intended for outpatient use. Among other changes, the updates modify the prescriber education blueprint to include more information on pain management and require manufacturers to make training available to other, non-physician prescribers, such as nurses and pharmacists involved in pain management. FDA announced the planned updates last year. In other news, the Centers for Disease Control and Prevention recently released a resource to help health care providers implement its guidelines for prescribing opioids for chronic pain.

Related News Articles

Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM)…
Headline
Mallinckrodt Pharmaceuticals today announced an agreement in principle on a settlement to resolve all opioid-related claims against the company in…
Headline
Public and private entities can apply for $1 million grants for a three-year period to enhance or expand opioid and other substance use disorder services in…
Headline
Rep. Vicky Hartzler, R-Mo., House Energy and Commerce Committee Ranking Member Greg Walden, R-Ore., and other Republicans on the committee last week asked the…
Headline
The House Energy and Commerce Subcommittee on Oversight and Investigations today held a hearing to highlight how federal funds have helped states combat…